Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile Spasm
Launched by KULLASATE SAKPICHAISAKUL · Mar 6, 2020
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how effective a combination of two treatments—vigabatrin and high-dose prednisolone—is for treating infantile spasms, a serious type of seizure disorder in babies. The goal is to see if using both treatments together works better than using vigabatrin alone. Infantile spasms can significantly affect a child's development, so finding the best treatment is very important.
To participate in this trial, children must be between 2 to 14 months old and diagnosed with infantile spasms by a pediatric neurologist. They also need to be Thai nationals. However, children who have been treated with vigabatrin or steroids in the last 28 days, or who have certain other health conditions, cannot join. Families interested in this study can expect regular check-ups and support throughout the trial. It's important to note that this study aims to provide more accessible treatment options for families in Thailand, especially since some treatments can be expensive or hard to find.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age at 2-14 months at date of enrollment
- • Clinical diagnosis of infantile spasm assessed by pediatric neurologist and hypsarrhythmic pattern or variants interpreted by pediatric epileptologist
- • Thai nationality
- Exclusion Criteria:
- • Previous treatment (within the last 28 days) with vigabatrin or corticosteroid
- • Previous diagnosis of epileptic encephalopathy e.g. early infantile epileptic encephalopathy and early myoclonic epileptic encephalopathy
- • Has a clinical suspicious or diagnosis of tuberous sclerosis complex characterized by one of these; known affected parent, previously diagnosed cardiac rhabdomyoma, hypomelanotic macules, forehead fibrous plaque, shagreen patch, retinal phakoma, or known polycystic kidneys
- • A contraindication to vigabatrin or corticosteroid such as recent varicella or herpes zoster infection, gastrointestinal hemorrhage etc.
- • Thai language ability of the parents or guardians is that they may not understand what is being requested of them.
- • Predictable lack of availability of follow up
About Kullasate Sakpichaisakul
Kullasate Sakpichaisakul is a dedicated clinical trial sponsor with a focus on advancing medical research and improving patient outcomes through innovative studies. With a strong commitment to ethical standards and regulatory compliance, Kullasate leads and collaborates on clinical trials that explore new therapies and treatment modalities across various therapeutic areas. The organization emphasizes rigorous scientific methodologies and patient-centered approaches, striving to contribute valuable insights to the medical community and enhance the quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ratchathewi, Bangkok, Thailand
Patients applied
Trial Officials
Kullasate Sakpichaisakul, MD
Principal Investigator
Queen Sirikit National Institute of Child Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials